An expert is one who knows more and more about less and less until he knows absolutely everything about nothing

Saturday, March 19, 2016

Investing in hepatitis C drugs could save the economy billions, researchers suggest

by Catharine Paddock PhD Medical News Today Researchers who examined the effect of treating hepatitis C patients with the newer generation of oral drugs suggest while these medications may cost tens of thousands of dollars for a 12-week course, they could avert billions in lost productivity. They conclude that the higher cure rate and reduced side effects of treating...

Hepatitis C treatments are ‘history in the making’ at a high cost !!

BillyBob McPherson lived on Ottawa’s streets as a young teenager before “running away with the carnival.” The 55-year-old doesn’t know exactly when during his colourful life he contracted hepatitis C — he thinks it might have been in Texas in the 1980s where he had surgery and blood transfusions while working as a carny. But without treatment, he believes, the disease...

Redhill Biopharma successfully meets primary endpoint in Phase III study of RHB-105 for H. pylori infection

RedHill Biopharma Ltd., an Israeli biopharmaceutical company focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced positive top-line results from its Phase III study with RHB-105 for the treatment of Helicobacter pylori (H. pylori) bacterial...

Lyxumia (lixisenatide) demonstrated cardiovascular safety in people with type 2 diabetes and high CV risk

Sanofi has announced the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia® (lixisenatide) in adults with type 2 diabetes and high CV risk. As previously reported, lixisenatide met the pre-specified criterion of non-inferiority versus placebo for the composite primary endpoint of CV death,...

Clinical trial using dorsaVi sensors demonstrates significant reduction in back pain

New data from a cluster randomised controlled trial has demonstrated that back pain patients monitored and treated using wearable movement sensors from dorsaVi Ltd (ASX:DVL) had a significant and sustained improvement in pain and functional ability.Across all primary outcome measures, participants treated with the dorsaVi sensors with biofeedback showed a 35 % to 47 %...

Massachusetts General Hospital launches phase II trial of BCG vaccine to reverse type 1 diabetes

FDA approval of trial testing generic vaccine announced at ADA Scientific Sessions A phase II clinical trial testing the ability of the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes has received approval from the U.S. Food and Drug Administration (FDA). The approval of this trial, which will shortly begin enrolling qualified patients,...


About Blogger:

Hi,I,m Basim from Canada I,m physician and I,m interested in clinical research feild and web development.you are more welcome in our professional website.all contact forwarded to basimibrahim772@yahoo.com.


Let's Get Connected: Twitter | Facebook | Google Plus| linkedin

 

Subscribe to us